Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6PN4H)

Drug Name

AjvW2 Drug Info

Synonyms

2,6-Piperazinedione, 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-, rel-; Icrf 193; ICRF-193; 21416-88-6; BRN 3981691; 2,6-Piperazinedione, 4,4'-(1,2-dimethylethylene)di-, meso-; 2,6-Piperazinedione, 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-, (R*,S*)-; AC1L3O6B; meso-2,3-Bis(3,5-dioxopiperazine-1-yl)butane; KBioSS_000487; BSPBio_001147; KBioGR_000487; SCHEMBL438498; CHEMBL264684; KBio3_000893; KBio3_000894; KBio2_003055; CHEBI:93771; KBio2_000487; KBio2_005623; HMS1990I09; HMS1792I09; Bio2_000884; HMS3403I09; Bio2_000404; HMS1362I09; ICRF

Indication

Disease Entry	ICD 11	Status	REF
Thrombosis	DB61-GB90	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DM6PN4H

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[2]
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)	TT38RM1	ITA2B_HUMAN; ITB3_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)	DTT	ITGA2B	2.186	1.202	1.585	2.7

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Thrombosis

ICD Disease Classification

DB61-GB90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)	DTT	ITGA2B; ITGB3	7.83E-01	-0.11	-0.45

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009728)
2	The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82.
3	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.